Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $88.2052W HIGH $132.60
Volume
1.81 M
Value Traded
164.65 M
Short % Float
4.99%
Days to Cover
5.3
-0.05%Week
-5.14%1 Month
-4.98%3 Month
+22.67%6 Month
+15.68%5 Year
+5,081.87%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
23.69 B
EPS (TTM)
7.95
P/E Ratio
14.69
Ent. Value
19.15 B
Total Shares
202.70 M
Float Shares
200.84 M
Insiders
0.91%
Institutions
103.70%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
INCY Catalyst Timeline
Dated clinical, regulatory and corporate events for Incyte Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Incyte Corporation
578Total events
31Upcoming
260Tier-1 (high impact)
2019 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationINCB161734Presentation
Updated Phase 1 INCB161734 data in PDAC presented in rapid oral session at ESMO 2026
pancreatic ductal adenocarcinoma (PDAC)source ↗
▲Oral PresentationINCA33890Presentation
Phase 1 INCA33890 data in MSS CRC presented in rapid oral session at ESMO 2026
microsatellite stable colorectal cancer (MSS CRC)source ↗
▲Partnership / LicenseINCB161734Corporate
New clinical trial collaborations with Bristol Myers Squibb and Synnovation to evaluate INCB161734 combinations in PDAC
pancreatic ductal adenocarcinoma (PDAC)source ↗
▲Partnership / LicenseRuxolitinibApprovedCorporate
Specialised Therapeutics expands Incyte partnership to commercialise ruxolitinib cream (Opzelura) in Australia
non-segmental vitiligo; atopic dermatitissource ↗
▲EU ApprovalRuxolitinibApprovedEx-US Regulatory
EC approval of Opzelura for moderate atopic dermatitis in adults
moderate atopic dermatitissource ↗
▼Program DiscontinuationINCB160058DiscontinuedCorporate
Discontinuation of INCB160058 development
▲AcquiredlatarcibartCorporate
Acquisition of Vega Therapeutics including latarcibart
von Willebrand diseasesource ↗
▲PublicationTafasitamabApprovedPresentation
Publication of frontMIND results in The Lancet
DLBCL and HGBLsource ↗
▲Full ResultsVGA039Clinical Data
Datos completos de seguridad y eficacia de dosis múltiples de VGA039 en ISTH 2026
enfermedad de von Willebrandsource ↗
◆Oral PresentationVGA039Presentation
Oral presentation at ISTH 2026 of VGA039 multiple-dose data
von-Willebrand-Syndromsource ↗
▲Oral PresentationVGA039Presentation
Phase 1/2 multidose data for VGA039 presented at ISTH 2026
Von Willebrand Diseasesource ↗
▲Oral PresentationlatarcibartPresentation
ISTH 2026 presentation of Phase 1/2 data for latarcibart
von Willebrand diseasesource ↗
▲PublicationTafasitamabApprovedPresentation
frontMIND results published in The Lancet
DLBCL and HGBLsource ↗
▼Program DiscontinuationINCB160058DiscontinuedCorporate
Discontinuation of INCB160058 development
▲CHMP Positive OpinionRuxolitinibApprovedEx-US Regulatory
Positive CHMP opinion for Opzelura cream in moderate atopic dermatitis
moderate atopic dermatitissource ↗
▲EU ApprovalTafasitamabApprovedEx-US Regulatory
Incyte Japan announces approval of Minjuvi (tafasitamab) in combination with lenalidomide for adults with relapsed or refractory DLBCL
relapsed or refractory diffuse large B-cell lymphoma (DLBCL)source ↗
▲Oral PresentationINCA033989Presentation
Positive Daten zu INCA033989 auf der EHA 2026 präsentiert
Myelofibrose; essenzielle Thrombozythämiesource ↗
◆Oral PresentationTafasitamabApprovedPresentation
Phase 3 frontMIND trial results presented at EHA 2026 plenary session
relapsed/refractory diffuse large B-cell lymphomasource ↗
▲Oral PresentationTafasitamabApprovedPresentation
Results from Phase 3 frontMIND trial of Tafasitamab combination presented at EHA 2026 Congress Plenary
Relapsed/Refractory Diffuse Large B-Cell Lymphomasource ↗
▲Oral PresentationINCA033989Presentation
Positive data presented at EHA 2026 for INCA033989 in essential thrombocythemia
Essential Thrombocythemiasource ↗
▲AcquiredCorporate
Incyte to acquire Vega Therapeutics for $1.25B upfront plus up to $750M in sales milestones
▲Primary Endpoint MetTafasitamabApprovedClinical Data
frontMIND study met primary endpoint: significant improvement in progression-free survival
diffuse large B-cell lymphomasource ↗
◆Topline ReadoutpovorcitinibFiledClinical Data
Topline Phase 3 data for povorcitinib in vitiligo expected mid-2026
nonsegmental vitiligosource ↗
◆Additional DataINCA033989Clinical Data
Updated Phase 1 data for INCA033989 in ET/MF anticipated mid-2026
second-line ET and myelofibrosissource ↗
◆FDA ApprovalRuxolitinibApprovedFDA Decision
Regulatory decision and potential launch for Jakafi XR in U.S. mid-2026
◆FDA ApprovalRuxolitinibApprovedFDA Decision
Expected regulatory decision and potential commercial launch for ruxolitinib XR
▲Oral PresentationTafasitamabApprovedPresentation
EHA 2026 Plenary presentation of frontMIND data
DLBCL and HGBLsource ↗
▲FDA ApprovalTafasitamabApprovedFDA Decision
Japan MHLW approval of Minjuvi for relapsed/refractory DLBCL
relapsed or refractory DLBCLsource ↗
▲Oral PresentationINCA033989Presentation
EHA 2026 presentation of updated Phase 1 data for INCA033989
mutCALR-positive ET and MFsource ↗
◆PublicationTafasitamabApprovedPresentation
Publication of frontMIND results in The Lancet
diffuse large B-cell lymphoma, high-grade B-cell lymphomasource ↗
▲Topline ReadoutTafasitamabApprovedClinical Data
Topline data: tafasitamab combination significantly prolonged progression-free survival, reducing risk of progression or death by 25%
linfoma difuso de células B grandes (LDCBG)source ↗
◆Oral PresentationTafasitamabApprovedPresentation
Full results of Phase 3 frontMIND study of tafasitamab plus lenalidomide and R-CHOP in newly diagnosed DLBCL presented at ASCO 2026
Diffuse Large B-cell Lymphoma (DLBCL)source ↗
▲Full ResultsTafasitamabApprovedClinical Data
Full results presented at ASCO and published in The Lancet
diffuse large B-cell lymphomasource ↗
◆Oral PresentationTafasitamabApprovedPresentation
Presentación oral de resultados completos del estudio frontMIND de fase 3 en ASCO 2026
linfoma difuso de células B grandes (DLBCL)source ↗
◆Full ResultsTafasitamabApprovedClinical Data
Resultados completos del estudio frontMIND de fase 3 presentados en ASCO 2026
linfoma difuso de células B grandes (DLBCL)source ↗
▲Partnership / LicenseCorporate
Strategic collaboration with Edison Scientific to employ Kosmos AI platform
◆Full ResultsRuxolitinibApprovedClinical Data
Datos a largo plazo de 24 semanas del ensayo de fase III TRuE-AD4 de Opzelura en dermatitis atópica moderada
dermatitis atópica moderadasource ↗
◆Full ResultsRuxolitinibApprovedClinical Data
Final 24-week data from Phase 3 TRuE-AD4 trial presented at EADV 2026
moderate atopic dermatitissource ↗
◆Oral PresentationRuxolitinibApprovedPresentation
Presentation at 2026 European Academy of Dermatology and Venereology (EADV)
moderate atopic dermatitissource ↗
▲Long Term DataRuxolitinibApprovedClinical Data
Final 24-week data from Phase 3 TRuE-AD4 of Opzelura cream in adults with moderate AD
moderate atopic dermatitissource ↗
●Poster PresentationRuxolitinibApprovedPresentation
TRuE-AD4 24-week data presented as poster at 2026 EADV Symposium
moderate atopic dermatitissource ↗
▲FDA ApprovalRuxolitinibApprovedFDA Decision
FDA approval of Jakafi XR (ruxolitinib) extended-release tablets for MF, PV, and GVHD
myelofibrosis, polycythemia vera, graft-versus-host diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How INCY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-26 | INCB161734 | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
31
Drugs Scored
rNPV / MCap
Top Drug
Top 3%
Mid Cap(rank 21 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| JAKAFI | |||
| OPZELURA | |||
| NIKTIMVO | |||
| MINJUVI/MONJUVI | |||
| ZYNYZ | |||
| ICLUSIG | |||
| PEMAZYRE |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| INCA33890 Small moleculeNCT07823322 | CRC (Colorectal Cancer) | Phase 3 | NOT YET_RECRUITING | 740 | May 14, 2029 | ||||||
| INCA33890 Small moleculeNCT05836324 | Solid Tumors | Phase 1 | RECRUITING | 570 | May 3, 2029 | ||||||
| povorcitinib Small moleculeNCT06212999 | Hidradenitis Suppurativa (HS) | Phase 3 | ACTIVE NOT_RECRUITING | 2,484 | Dec 26, 2026 | ||||||
| povorcitinib Small moleculeNCT06113471 | NonSegmental Vitiligo | Phase 3 | ACTIVE NOT_RECRUITING | 917 | Mar 16, 2027 | ||||||
| povorcitinib Small moleculeNCT06516952 | Prurigo Nodularis | Phase 3 | ACTIVE NOT_RECRUITING | 695 | May 3, 2027 | ||||||
| povorcitinib Small moleculeNCT05851443 | Moderate to Severe Asthma | Phase 2 | ACTIVE NOT_RECRUITING | 247 | Jul 5, 2027 | ||||||
| INCB161734 Small moleculeNCT06179160 | Solid Tumors | Phase 3 | RECRUITING | 1,298 | Jan 1, 2027 | ||||||
| INCB161734 Small moleculeNCT07853040 | Hepatic Insufficiency | Phase 1 | NOT YET_RECRUITING | 24 | Mar 31, 2027 | ||||||
| INCB161734 Small moleculeNCT07854249 | Renal Insufficiency | Phase 1 | NOT YET_RECRUITING | 24 | Mar 30, 2027 | ||||||
| VGA039 Small moleculeNCT05776069 | Von Willebrand Diseases | Phase 3 | RECRUITING | 176 | Dec 1, 2029 | ||||||
| INCA034176 Monoclonal antibodyNCT06843408 | Chronic Graft-versus-host-disease | Phase 3 | ACTIVE NOT_RECRUITING | 362 | Jul 20, 2028 | ||||||
| parsaclisib Small moleculeNCT04509700 | B-Cell Malignancies | Phase 2 | ACTIVE NOT_RECRUITING | 200 | Nov 5, 2026 | ||||||
| INCB123667 Small moleculeNCT07797283 | Ovarian Cancer | Phase 3 | NOT YET_RECRUITING | 1,216 | May 1, 2034 | ||||||
| INCB123667 Small moleculeNCT05238922 | Solid Tumors | Phase 1 | ACTIVE NOT_RECRUITING | 291 | Aug 31, 2027 | ||||||
| INCB123667 Small moleculeNCT07559474 | Hepatic Insufficiency | Phase 1 | RECRUITING | 16 | Apr 13, 2027 | ||||||
| INCB123667 Small moleculeNCT07559396 | Renal Impairment | Phase 1 | RECRUITING | 16 | Jan 4, 2027 | ||||||
| INCB000928 Small moleculeNCT05090891 | Fibrodysplasia Ossificans Progressiva (FOP) | Phase 2 | RECRUITING | 98 | Jan 20, 2033 | ||||||
| INCA033989 Small moleculeNCT07623200 | Essential Thrombocythemia | Phase 3 | RECRUITING | 426 | Nov 1, 2030 | ||||||
| INCA033989 Small moleculeNCT05936359 | Myeloproliferative Neoplasms | Phase 1 | ACTIVE NOT_RECRUITING | 450 | Feb 29, 2028 | ||||||
| INCA035784 Small moleculeNCT07008118 | Myeloproliferative Neoplasms | Phase 1 | RECRUITING | 120 | Dec 14, 2029 | ||||||
| INCA000585 Small moleculeNCT07104565 | Immune Thrombocytopenia | Phase 2 | RECRUITING | 56 | Mar 9, 2028 | ||||||
| INCB186748 Small moleculeNCT06818812 | Solid Tumors | Phase 1 | ACTIVE NOT_RECRUITING | 30 | Mar 27, 2027 | ||||||
| Ruxolitinib Small moleculeNCT06958211 | Hidradenitis Suppurativa | Phase 3 | ACTIVE NOT_RECRUITING | 1,246 | Jul 11, 2027 | ||||||
| Ruxolitinib Small moleculeMarketedNCT06548360 | NonSegmental Vitiligo | Phase 3 | RECRUITING | 430 | Dec 20, 2028 | ||||||
| Ruxolitinib Small moleculeMarketedNCT06832618 | Atopic Dermatitis | Phase 3 | ACTIVE NOT_RECRUITING | 2,348 | Sep 6, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every INCY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| INCB161734 | pancreatic ductal adenocarcinoma | Phase 1 | 2026-10-26 | m FOLFIRINOX: ORR 89% and 81%, DCR 100%, PFS 90%, median treatment duration 6 months, TRAEs diarrhea 68%, nausea 64%, vomiting 57%, decreased neutrophil count 57%; GEMNab P: ORR 69% and 58%, DCR 96%, PFS 80%Read More | Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| CAGNONI PABLO JOfficer (President, Global Head of R&D) | Option | 839 184,039 held | $71.93 | 10/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INCY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 17.5 % (5.4 %) | 3.49 B | 30.76 M | 0.06% ( 17.92 K) |
INCY Institutional Ownership Trends
INCY Short Interest
Shares sold short, counted twice a month.
4.99%
Short % of Float
of tradable shares sold short
10.0M
Shares Sold Short
+0.4% vs prior count
5.3 High
Days to Cover
trading days of normal volume to buy every short share back
1.9M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INCY ranks across every disease it competes in
Competitive Position is a premium feature
See how INCY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINCY News
INCY▲ +0.2%today
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
Incyte presented new data on its gastrointestinal cancer portfolio at ESMO 2026, focusing on INCB161734 and INCA338901. The data support ongoing trials in pancreatic ductal adenocarcinoma and colorectal cancer, with promising efficacy and safety profiles. New collaborations aim to enhance treatment options for patients with KRAS G12D mutations.
Read more →INCYIncyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
Incyte will present new oncology data at the ESMO Congress 2026, showcasing investigational therapies INCB161734 and INCA338901. These presentations are part of ongoing Phase 3 programs aimed at treating advanced gastrointestinal cancers. An investor event will also be held to discuss the findings and provide portfolio updates.
Read more →INCYIncyte Honors the 2026 MPN Heroes®, Celebrating Champions of the Myeloproliferative Neoplasm (MPN) Community
Incyte has announced the winners of the 2026 MPN Heroes program, recognizing eight individuals for their impactful contributions to the myeloproliferative neoplasm (MPN) community. These honorees have been acknowledged for their dedication to patient care, research, and advocacy. The awards will be presented at an event in New Orleans during the ASH 2026 Annual Meeting.
Read more →INCYIncyte to Report Third Quarter Financial Results
Incyte Corporation is set to announce its financial results for the third quarter of 2026. The announcement will provide insights into the company's performance and financial health during this period. Investors and stakeholders are likely to be keenly awaiting these results to gauge future prospects.
Read more →INCYIncyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio
Incyte presented data at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, emphasizing the extensive range of its inflammation and autoimmunity portfolio. This event underscores the company's commitment to advancing treatments in these therapeutic areas.
Read more →INCYSpecialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia
Specialised Therapeutics has expanded its partnership with Incyte to include the commercialization of ruxolitinib cream (Opzelura®) in Australia. This topical JAK inhibitor is indicated for treating non-segmental vitiligo and atopic dermatitis. ST will handle regulatory submissions and distribution, while Incyte will manage development and manufacturing. The collaboration aims to improve access to this treatment for Australian patients.
Read more →INCYIncyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program
Incyte announced that MINJUVI® (tafasitamab) is now publicly funded in Ontario for patients with relapsed or refractory follicular lymphoma through the FAST Program. This funding allows eligible patients to access treatment sooner while formal reimbursement processes are underway. The move highlights Ontario's commitment to innovative cancer care and addresses the critical need for new treatment options.
Read more →INCYIncyte to Present at Upcoming Investor Conferences
Incyte has announced its participation in several upcoming investor conferences in September 2026. The company will present at the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Morgan Stanley Global Healthcare Conference. These presentations will be available via live webcast and for replay for 30 days, highlighting Incyte's focus on investor engagement.
Read more →INCYGlobal Vitiligo Foundation Applauds Incyte’s “Moments of Clarity” Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness
The Global Vitiligo Foundation has endorsed Incyte's 'Moments of Clarity' campaign, which focuses on sharing personal stories of individuals living with nonsegmental vitiligo. This initiative aims to enhance awareness and understanding of the condition, aligning with the foundation's goals of education and community support for affected individuals.
Read more →INCYIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Incyte Corporation has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This rule allows companies to grant stock options or other equity awards to new employees as an inducement to join the company. The announcement was made from Wilmington, Delaware.
Read more →INCYOpzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
Incyte's Opzelura (ruxolitinib) cream has received European Commission approval for treating moderate atopic dermatitis in adults. This marks the first steroid-free topical JAK inhibitor approved in the EU, based on positive Phase 3b TRuE-AD4 study results. The treatment showed significant improvements in clinical signs and symptoms, providing a new option for patients inadequately managed by existing therapies.
Read more →INCY▲ +9.3%on this newsshared move
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
Incyte Corporation has released its financial results for the second quarter of 2026, along with updates regarding its business operations. The report provides insights into the company's performance and strategic direction. Further details on specific financial metrics and business developments were not disclosed in the article.
Read more →INCYIncyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
Incyte will showcase data in four rapid oral presentations at the ESMO Congress 2026. This initiative aims to enhance treatment outcomes for patients with difficult-to-treat cancers. The presentations underscore Incyte's dedication to advancing cancer research and improving therapeutic strategies.
Read more →INCYIncyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
Incyte has presented promising Phase 1/2 multidose data for VGA039 (Latarcibart) at ISTH 2026. The results indicate substantial reductions in bleeding episodes among patients suffering from all types of Von Willebrand Disease. This development highlights the potential of VGA039 as a treatment option in this patient population.
Read more →INCYIncyte to Report Second Quarter Financial Results
Incyte has announced a conference call and webcast to discuss its second quarter financial results for 2026. The event is scheduled for July 28, 2026, with the press release set to be issued at 7:00 a.m. ET. This initiative demonstrates the company's commitment to keeping investors informed.
Read more →INCYIncyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
Incyte has successfully completed the acquisition of Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics. This strategic move is aimed at expanding Incyte's hematology portfolio, thereby enhancing its capabilities and market presence in this therapeutic area. The acquisition is expected to contribute positively to Incyte's growth trajectory.
Read more →INCY▲ +5.8%on this newsshared move
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Incyte has received a positive opinion from the CHMP regarding its product Opzelura® (ruxolitinib) cream. This recommendation is aimed at treating adults suffering from moderate atopic dermatitis. The positive opinion marks a significant advancement in the regulatory process, potentially leading to approval for this new treatment option.
Read more →INCY▲ +5.5%on this newsshared move
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Incyte Japan has announced the approval of Minjuvi® (tafasitamab) in combination with Lenalidomide for treating adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval marks a significant advancement in treatment options for patients facing this challenging condition. The combination therapy aims to improve patient outcomes and address unmet medical needs.
Read more →INCY▼ -6%on this newsshared move
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
Incyte has announced promising new data regarding INCA033989 at the EHA 2026 conference. The data indicates that the treatment achieved rapid and robust clinical and molecular responses in patients with myelofibrosis and essential thrombocythemia. Additionally, the treatment was reported to be well tolerated, highlighting its potential benefits.
Read more →INCY▼ -6%on this newsshared move
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
Incyte presented results from the pivotal Phase 3 frontMIND trial of Tafasitamab at the 2026 EHA Congress. The trial showed prolonged progression-free survival for patients receiving Tafasitamab in combination therapy. Further details on the trial's outcomes and implications for treatment were discussed during the plenary session.
Read more →About Incyte Corporation
Headquarters1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803
BIOPHARMAWATCH ELITE PLUS
Trade the next INCY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime